These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37864131)

  • 1. Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.
    Zhou Y; Lu T; Li Y; Qin Y; Lu Y; Tian Q; Lan K; Zhou G; Qin Y; Harypursat V; Li S; Lin S; Chen Y
    BMC Infect Dis; 2023 Oct; 23(1):707. PubMed ID: 37864131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.
    Zhou Y; Qin Y; Lu Y; Yuan J; Nie J; Liu M; Tian Q; Lan K; Zhou G; Qin Y; He K; Yu J; Jiang Z; Liu J; Liu S; Harypursat V; Chen Y
    Infect Dis Ther; 2022 Aug; 11(4):1575-1590. PubMed ID: 35689792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
    Le T; Kinh NV; Cuc NTK; Tung NLN; Lam NT; Thuy PTT; Cuong DD; Phuc PTH; Vinh VH; Hanh DTH; Tam VV; Thanh NT; Thuy TP; Hang NT; Long HB; Nhan HT; Wertheim HFL; Merson L; Shikuma C; Day JN; Chau NVV; Farrar J; Thwaites G; Wolbers M;
    N Engl J Med; 2017 Jun; 376(24):2329-2340. PubMed ID: 28614691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study.
    Huang W; Li T; Zhou C; Wei F; Cao C; Jiang J
    Mycopathologia; 2021 May; 186(2):269-276. PubMed ID: 33616828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
    Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
    Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
    Bicanic T; Bottomley C; Loyse A; Brouwer AE; Muzoora C; Taseera K; Jackson A; Phulusa J; Hosseinipour MC; van der Horst C; Limmathurotsakul D; White NJ; Wilson D; Wood R; Meintjes G; Harrison TS; Jarvis JN
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7224-31. PubMed ID: 26349818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating progressive disseminated histoplasmosis in people living with HIV.
    Murray M; Hine P
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013594. PubMed ID: 32343003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological toxicities associated with amphotericin B formulations.
    Falci DR; da Rosa FB; Pasqualotto AC
    Leuk Lymphoma; 2015; 56(10):2889-94. PubMed ID: 25629990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
    Zhao T; Xu X; Wu Y; Zhang W; Zeng Q; Lu Y; Yang T; Zhou G; Yu J; Lan K; Harypursat V; Chen Y
    BMC Infect Dis; 2022 Aug; 22(1):677. PubMed ID: 35941618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for HIV-associated cryptococcal meningitis.
    Tenforde MW; Shapiro AE; Rouse B; Jarvis JN; Li T; Eshun-Wilson I; Ford N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD005647. PubMed ID: 30045416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antifungal therapy for cryptococcal meningitis.
    Day JN; Chau TTH; Wolbers M; Mai PP; Dung NT; Mai NH; Phu NH; Nghia HD; Phong ND; Thai CQ; Thai LH; Chuong LV; Sinh DX; Duong VA; Hoang TN; Diep PT; Campbell JI; Sieu TPM; Baker SG; Chau NVV; Hien TT; Lalloo DG; Farrar JJ
    N Engl J Med; 2013 Apr; 368(14):1291-1302. PubMed ID: 23550668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.
    Shi M; Qin Y; Chen S; Wei W; Meng S; Chen X; Li J; Li Y; Chen R; Su J; Yuan Z; Wang G; Qin Y; Ye L; Liang H; Xie Z; Jiang J
    PLoS Negl Trop Dis; 2023 Oct; 17(10):e0011622. PubMed ID: 37816066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia.
    Shigemi A; Matsumoto K; Ikawa K; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2011 Nov; 38(5):417-20. PubMed ID: 21885259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.
    Xue X; Zou J; Fang W; Liu X; Chen M; Arastehfar A; Ilkit M; Zheng Y; Qin J; Peng Z; Hu D; Liao W; Pan W
    Mycopathologia; 2022 Jun; 187(2-3):169-180. PubMed ID: 35157189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by
    Le T; Ly VT; Thu NTM; Nguyen A; Thanh NT; Chau NVV; Thwaites G; Perfect J; Kolamunnage-Dona R; Hope W
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort.
    Klus J; Ly VT; Chan C; Le T
    Med Mycol; 2021 Apr; 59(4):392-399. PubMed ID: 33644813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of early fungicidal activity and mortality between daily liposomal amphotericin B and daily amphotericin B deoxycholate among patients with HIV-associated cryptococcal meningitis.
    Kimuda S; Kwizera R; Dai B; Kigozi E; Kasozi D; Rutakingirwa MK; Tukundane A; Shifah N; Luggya T; Luswata A; Ndyetukira JF; Yueh S; Mulwana S; Wele A; Bahr NC; Meya DB; Boulware DR; Skipper CP
    Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38943665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.
    Botero Aguirre JP; Restrepo Hamid AM
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010481. PubMed ID: 26595825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.